What are the clinical indications for hyoscine (scopolamine)?

Hyoscine (Scopolamine) Clinical Indications

Hyoscine is indicated for postoperative nausea and vomiting prevention, reduction of excessive respiratory secretions in dying patients, motion sickness prevention, and treatment of abdominal cramping from gastrointestinal spasms.

Primary Indications

1. Postoperative Nausea and Vomiting (PONV)

Transdermal scopolamine is effective for PONV prevention when applied preoperatively, reducing postoperative vomiting by approximately 17 patients per 100 treated compared to placebo 1, 2. The patch should be applied the evening before or 4 hours before surgery, as onset takes approximately 12 hours 3.

• Dosing: Transdermal patch 1.5 mg (releases 0.5 mg over 72 hours at 5 mcg/hour) 4
• Timing: Apply 4-12 hours preoperatively for optimal effect 2
• Efficacy: Number needed to treat = 6 for preventing vomiting 5
• Cesarean delivery: Anticholinergic agents like scopolamine effectively reduce postoperative nausea and vomiting (moderate evidence, strong recommendation) 1

Important caveat: Transdermal patches cause visual disturbances in 18% and dry mouth in 8% of patients 5. For high-risk patients undergoing liver surgery, scopolamine patches should be avoided in elderly patients due to delirium risk 6.

2. Death Rattle (Excessive Respiratory Secretions)

Scopolamine is a first-line option to reduce excessive secretions associated with dyspnea in dying patients 3, 7.

• Subcutaneous dosing: 0.25 mg bolus followed by continuous infusion 8
• Transdermal: 1.5-3 mg patch every 72 hours 7
• Efficacy: Equally effective as atropine (0.5 mg) or hyoscine butylbromide (20 mg), with 42% of patients achieving non-disturbing intensity within 1 hour 8

Critical timing consideration: Transdermal patches have 12-hour onset and are inappropriate for imminently dying patients—use subcutaneous injection instead 3.

3. Motion Sickness Prevention

Scopolamine is the most effective single agent for motion sickness prevention 4, 9.

• Transdermal patch: Apply 4-12 hours before travel exposure
• Evidence: Superior to placebo with odds ratio of 0.69 for preventing nausea and vomiting 9
• Duration: Effective for 72 hours of continuous protection 4

4. Abdominal Cramping and Pain

Hyoscine butylbromide (not scopolamine hydrobromide) is indicated for abdominal pain from gastrointestinal spasms 10.

• Mechanism: Anticholinergic with high affinity for GI smooth muscle muscarinic receptors
• Advantage: Minimal systemic absorption (<1% bioavailability), so primarily local GI effect with fewer central side effects 10
• Note: This is a different formulation than scopolamine used for PONV or motion sickness

5. Opioid-Induced Nausea

Scopolamine may be considered as alternative antiemetic therapy for persistent opioid-induced nausea when first-line agents (phenothiazines, dopamine antagonists, 5-HT3 antagonists) fail 11.

Contraindications and Populations to Avoid

Absolute Avoidance:

• Elderly patients: High risk of delirium and anticholinergic syndrome 6, 12
• Pediatric patients: Increased risk of adverse anticholinergic effects 12
• Patients with urinary retention risk: Particularly after urogynecologic surgery (RR 2.35 for postoperative urinary retention) 13
• Mechanical bowel obstruction: When using for nausea (use octreotide instead) 14

Relative Contraindications:

• Asthma, cardiovascular disease, diabetes, gangrene 15
• Patients requiring intact cognitive function perioperatively
• Those with glaucoma or urogenital tract obstruction

Practical Prescribing Algorithm

For PONV prevention:

1. Identify high-risk patients (≥2 Apfel risk factors)
2. If elderly or pediatric → avoid scopolamine, use ondansetron + dexamethasone instead 16
3. If adult, non-elderly → apply transdermal patch evening before surgery
4. Combine with other antiemetic classes for multimodal approach 1, 16

For death rattle:

1. If patient imminently dying (hours) → subcutaneous 0.25 mg bolus + infusion 3
2. If patient has days remaining → transdermal patch acceptable 3
3. Monitor for delirium, especially if on other anticholinergics 7

For motion sickness:

1. Apply patch 4-12 hours before travel
2. Counsel on 18% risk of visual disturbances, 8% dry mouth 5
3. Ensure proper application (common user error in 1-13% of patients) 5

Key Safety Considerations

• Central anticholinergic syndrome: Rare but severe idiosyncratic reaction with psychosis, hallucinations, ataxia, and self-mutilation reported even with peripheral formulations 17
• Drug interactions: Grapefruit juice increases scopolamine bioavailability by 142% through CYP3A inhibition 4
• Pregnancy: Crosses placenta; use only under observation 4
• Onset variability: Oral/parenteral forms have rapid onset (0.5 hours), but transdermal requires 8-12 hours to therapeutic levels 4, 5